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Clinical Science Articles
Relief of Nocturnal Enuresis by Desmopressin Is Kidney and
Vasopressin Type 2 Receptor Independent
Joris H. Robben,* Mozes Sze,* Nine V. Knoers,† Paul Eggert,‡ Peter Deen,* and
Dominik Mu¨ller§
*Department of Physiology, Nijmegen Centre of Molecular Life Sciences, and †Department of Human Genetics,
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands; and ‡University Children’s Hospital, Kiel, and
§Department of Pediatric Nephrology, Charite´ Berlin, Berlin, Germany
Primary nocturnal enuresis (PNE) is a common problem in childhood and adolescence. Although various treatments are highly
effective, a common underlying hypothesis on the pathogenesis is lacking. The success of desmopressin, a synthetic analogue
of the antidiuretic hormone vasopressin, has been attributed to increased renal water reabsorption that is mediated by
activation of the renal vasopressin V2 receptor (V2R). However, this effect does not explain other symptoms of PNE, such as
the failure to arouse upon bladder distension. This study identified a family in which one child displayed PNE and coexisting
nephrogenic diabetes insipidus, as a result of a novel nonsense mutation in the V2R gene (C358X). Cell-biologic investigations
revealed that V2R-C358X is retained in the endoplasmic reticulum and is unstable, which explains his nephrogenic diabetes
insipidus. Consistently, extrarenal V2R-mediated responses were absent in the patient who was treated with desmopressin.
Administration of desmopressin, however, changed his PNE into nocturia, because he now still voided unchanged high
urinary volumes at night but woke up and went to the bathroom. Withdrawal of desmopressin was accompanied by
bedwetting, whereas reintroduction again relieved the symptoms. Therefore, these data indicate that neither a functioning
renal concentration system nor a functional V2R is needed for the therapeutic benefit of desmopressin in PNE. Rather, it
suggests that another vasopressin receptor and other organ(s) is the target for desmopressin to relieve PNE.
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T he major role of the vasopressin type-2 receptor (V2R)is the regulation of the body water homeostasis bydetermining the level of reabsorption of water from
pro-urine through aquaporin-2 (AQP2) water channels. In
states of hypovolemia or hypernatremia, as well as during sleep
when there is functional antidiuresis, the release of the antidi-
uretic hormone arginine-vasopressin (AVP) from the pituitary
is increased. Upon binding of AVP to its V2R, it activates
adenylate cyclase via a stimulatory G protein. The subsequent
increase of intracellular cAMP induces protein kinase A to
phosphorylate, among other proteins, AQP2, which is then
redistributed from intracellular vesicles to the apical mem-
brane. Driven by the sodium and urea gradient, water is sub-
sequently reabsorbed from the pro-urine through AQP2, result-
ing in concentrated urine. Removal of AVP reverses this
process, restoring the water-impermeable state of the apical
membrane and occurrence of diluted urine. Mutations in the
human V2R result in X-linked nephrogenic diabetes insipidus
(NDI), a disorder in which patients are unable to concentrate
their urine in response to AVP, resulting in the excretion of
large volumes of diluted urine (1–3).
Primary nocturnal enuresis (PNE) is defined as the persis-
tence of nightly bedwetting in children who are at least 5 yr of
age and is one of the most frequent complaints in pediatric and
urologic practice. Although the frequency of enuretic episodes
in a child is not clearly defined, at least three episodes per week
in a patient who has never been continuously dry for longer
than 6 mo is generally accepted for the diagnosis of PNE (4,5).
Despite a maturation rate of 15% per year, 0.5% of all cases
remain in adulthood, with serious effects on self-esteem (6).
Among various hypotheses on the pathophysiology of PNE, it
has been proposed that patients with PNE have insufficient
nightly increase of AVP, leading to the production of large
amounts of dilute urine, thereby surpassing the bladder capac-
ity (7). Successful application of a synthetic analogue of AVP,
desmopressin (dDAVP), a V2R agonist, seemed to confirm this
hypothesis. One of the major criticisms of this concept, how-
ever, is that patients with PNE do not wake up before, during,
or after voiding, which is difficult to explain by an increased
urine production or by a small functional bladder capacity.
Here, we describe the identification of a family with two
brothers with NDI as a result of a mutation in the V2R gene
(Xq28) leading to a premature stop codon (C358X) in the V2R
protein. Besides NDI, one patient also experiences PNE. Ad-
ministration of desmopressin and the use of alarm treatment
relieved PNE completely, whereas NDI remained unaffected.
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Cell biologic characterization of this novel mutation revealed
instability and retention in the endoplasmic reticulum of the
mutant V2R protein, thereby explaining underlying NDI. These
findings not only exclude a functioning urinary concentration
system as a prerequisite for the beneficial action of desmopres-
sin in PNE but also reveal that this effect is V2R independent.
Materials and Methods
Patient Analysis
Serum and urinary electrolyte levels and osmolalities, vasopressin
levels, and body weight and BP were measured by standard proce-
dures. A thirst trial with additional infusion of desmopressin (0.3
g/kg body wt) at 7 h after the start of the thirst trial was done as
described previously (8). According to established standards, the test
was stopped when clinical symptoms such as severe arterial hypoten-
sion and tachycardia occurred for more than three subsequent mea-
surements or when body weight was reduced by10% during the trial.
The activities of von Willebrand factor and clotting factor VIII were
determined as described previously (8).
When the indomethacin (3 mg/kg body wt per d) and hydrochlo-
rothiazide (HCT; 1 mg/kg body wt per d) treatment was started, it
reduced urinary volumes by approximately one third (daytime output
5.1 ml/kg body wt; nighttime output 5.0 ml/kg body wt). Parent’s
informed consent was obtained for all studies, and all clinical experi-
ments were performed in accordance to the Declaration of Helsinki.
Isolation of genomic DNA, amplification of the V2R coding regions,
and sequence analyses were done as described previously (9,10).
Expression Constructs
The pEGFP-N1-wtV2R expression construct was a gift of Dr. Alex-
ander Oksche (FMP, Berlin, Germany). To allow N-terminal detection
of the V2R, a FLAG-tag was fused to the N-terminus using the PCR
with the sense primers 5-ATGGACTACAAGGATGACGATGA-
CAAGACCATGCTCATGGCGTCCACCAC-3 (FLAG-encoding se-
quence in bold) and the antisense primer 5-GCTGAGAAGGAGC-
GAGAAG-3. In a second PCR reaction, using the same antisense
primer and the sense primer 5-GTCTACTCGAGCCACCATGGAC-
TACAAG-3, an XhoI site and the Kozak sequence (indicated in bold)
were added to the 5 end of the first PCR product. The resulting 529-bp
PCR product was cut with XhoI and PstI and cloned into the XhoI/PstI
digested pEGFP-N1-V2R construct to yield pEGFP-N1-FLAG-V2R.
Site-directed mutagenesis was performed on pEGFP-N1-wtV2R as de-
scribed previously (11) using the sense primer 5-CAAGATGAGTCCT-
GAACCACCGCCAGCTC-3 (C358X; mutated codon indicated in bold)
and its complementary antisense primer. After correct clones were
digested with HindIII and BamHI (C358X), the mutation-containing
fragment was isolated and cloned into the corresponding sites of the
pEGFP-N1-FLAG-V2R. Sequence analysis of selected clones confirmed
that only the desired mutations were introduced.
Cell Culture and Transfection
Maintenance of MDCK type I cells and generation of stable clones
were performed as described previously (8). COS-M6 cells were main-
tained and transfected with 1 g of expression construct (unless indi-
cated otherwise) as described previously (11). Before analysis, COS
cells that transiently expressed FLAG-wtV2R-GFP or FLAG-V2R-
C358X were seeded in six multiwell plates (Costar, Cambridge, MA),
and grown for 2 d.
RNA Isolation and Northern Blotting
Transiently transfected COS cells were trypsinized and subsequently
counted. Total RNA of 5 million cells was isolated using the RNeasy kit
(Qiagen, Hilden, Germany) according to the manufacturer’s protocol.
Ten micrograms of total RNA was run on a 1% Agarose/MOPS gel
with 7% formaldehyde and subsequently transferred to a nitrocellulose
blot. V2R mRNAwas detected using a [32P]-labeled cDNA probe of 0.65
kb corresponding to the PstI-HindIII fragment of the V2R coding se-
quence.
Immunoblotting and Immunocytochemistry
PAGE and immunoblotting were performed as described previously
(12). Immunodetection was performed using 1:5000 diluted peroxidase-
conjugated mouse anti-FLAG antibodies (Sigma, St. Louis, MO). Im-
munocytochemistry and confocal laser scanning microscopy were per-
formed as described previously (12). For immunocytochemistry under
nonpermeabilized conditions, cells were incubated for 1 h at 4°C with
1:100 diluted mouse anti-FLAG antibodies (Sigma) in PBS supple-
mented with 1 mMMgCl2 and 0.1 mM CaCl2. As secondary antibodies,
1:100-diluted goat anti-mouse coupled to Alexa-594 (Molecular Probes,
Leiden, The Netherlands) was used.
Results
Patient Analysis
The oldest son of a white, nonconsanguineous family was
born in the 34th week of gestation (Figure 1). Polyhydramnios
was noted during pregnancy. After birth, the child developed
poorly with vomiting and repeated episodes of hyperpyrexia.
Age-related height and weight remained below the third per-
centiles. High serum sodium (serum Na 158 mmol/L) and
polyuria (8.2 ml/kg body wt per h) pointed to a renal concen-
tration defect. To establish whether our male proband had NDI,
we performed a first thirst trial combined with desmopressin
infusion when he was 4 yr of age. This revealed unchanged
urinary osmolalities between the start (235 mosmol/kg H2O)
and end (229 mosmol/kg H2O) of the treatment. Table 1 dis-
plays the biochemical and physiologic data during this thirst
trial. For confirmation of the diagnosis of NDI in the absence of
mutation analysis, which was not available at that time, two
subsequent thirst-desmopressin trials were done at 4.5 and 5 yr
of age. These revealed urinary osmolalities of 112 and 101
mosmol/kg H2O (trial 1) and 150 and 138 mosmol/kg H2O
Figure 1. Pedigree of the family. f, Patients with nephrogenic
diabetes insipidus (NDI). PNE, primary nocturnal enuresis; wt,
wild-type. The vasopressin V2 receptor (V2R) gene is located
on the X-chromosome; therefore, male family members have
only one copy of the gene.
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(trial 2) before and after treatment, respectively. On the basis of
these data, NDI was diagnosed. The child was started on HCT
and indomethacin after the last thirst trial was completed, and
the diagnosis of NDI was established. For further determina-
tion of whether daytime and nighttime urine volumes differed
with the patient under adequate NDI treatment, 12-h diurnal
and nocturnal urine volumes were measured on repetitive mea-
surements (four samplings) over a 12-mo period. However, the
median diurnal (8.5 ml/kg body wt; range 6.9 to 11.2) and
nocturnal (8.8 ml/kg body wt; range 5.2 to 11.4) urine volumes
did not differ. Note that measurements were used only when
bedwetting had not occurred during the night.
X-linked NDI is due to mutations in the V2R gene, whereas
mutations in the AQP2 water channel gene cause autosomal
NDI. Besides their ability to induce urine concentration, AVP
and desmopressin are known to increase levels and therewith
the activities of von Willebrand factor and blood clotting factor
VIII in plasma. Because this occurs through activation of the
V2R, this response is absent in patients with inactivating mu-
tations of the V2R gene but is unaffected in patients with NDI
and AQP2 gene mutations (8). To discriminate between these
two, we therefore these factors measured after infusion of des-
mopressin (0.3 g/kg body wt). However, no changes in the
activity of von Willebrand factor and clotting factor VIII were
found (Figure 2), which indicated that a V2R defect is the
molecular cause of NDI.
Patient Responses to Desmopressin
Ever since birth and despite the indomethacin/HCT treat-
ment started at age 5, the patient wet his bed at night without
waking up. At the age of 10 and during an observation period
of 3 mo, he wet his bed on average at least three times per week
(as assessed by a chart completed by the parents; Table 2),
consistent with the diagnosis of PNE. Then, desmopressin ad-
ministration (20 g intranasally before going to bed) was initi-
ated 1 mo after indomethacin and HCT administration was
stopped. After 3 d, the child did not wet his bed anymore but
woke up and went to the toilet instead. Withdrawal of the
medication after 3 mo of dryness resulted in recurrence of PNE,
whereas reintroduction after 4 wk again led to disappearance of
PNE. The treatment left the urinary volume unchanged (before
9.1 ml/kg body wt per h [9.0 daytime and 9.2 nighttime] and
9.3 ml/kg body wt per h during treatment [9.2 daytime and 9.4
nighttime]). Reintroduction of indomethacin and HCT treat-
ment, together with desmopressin, reduced urinary volume
Figure 2. Activity of von Willebrand factor and clotting factor
VIII (%) after dDAVP infusion (0.3 g/kg) in the patient with
PNE-NDI. At time 0 min, desmopressin (0.3 g/kg body wt)
was infused, followed by measurement of von Willebrand fac-
tor and clotting factor VIII responses at the indicated time
points. Methods after Bichet et al. (8).
Table 2. Frequency of enuretic episodes for periods of
various medical treatmentsa
Treatment
Observation
Period
(mo)
Enuretic
Events/Wk
(Median
Range)
HCT and Indomethacin 3 6 (4 to 7)
Off medication 1 5 (4 to 7)
Desmopressin 3 0 (0 to 1)
Off medication 1 5 (4 to 7)
Desmopressin 3 0 (0 to 1)
Desmopressin, HCT,
indomethacin
3 0 (0 to 1)
aDosages were 1 and 3 mg/kg body wt per d for
hydrochlorothiazide (HCT) and indomethacin and 20 g
nasal spray/d for desmopressin. Note that the thirst trial was
performed during daytime.
Table 1. Thirst trial: Given are the biochemical and clinical data of the patient during the first thirst triala
Parameter Before 1 h 2 h 3 h 4 h 5 h 6 h
7 h
(Desmo-
pressin)
8 h 9 h(End)
Body weight (kg) 12.2 12.0 11.8 11.5 11.0 10.9 10.5 10.4 10.3 10.1
Blood pressure (mmHg) 73/55 83/56 95/67 84/56 79/51 65/49 59/45 51/43 48/34 45/37
Heart rate (bpm) 102 103 97 112 114 111 123 122 131 133
S-Osmol (mosmol/kg H2O) 297 302 314 321 325 326 329 330 335 339
U-Osmol (mosmol/kg H2O) 235 238 225 205 204 210 223 222 229 229
U-Vol (ml/kg per h) 10.5 10.3 10.2 12.5 9.5 8.7 8.2 8.3 8.8 9.1
U-Ca2 (mmol/kg per 24 h) 0.04
Vasopressin (ng/L) 84 75 94
Platelet count (per nl) 420 396 432 434 444 431 444 471 495 491
aS-Osmol, serum osmolality; U-Osmol, urinary osmolality; U-Vol, urinary volume; U-Ca2, urinary calcium.
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again by approximately one third. The number of enuretic
events during the various periods is given in Table 2.
V2R Gene Mutation and Sibling Responses
For identification of the V2R gene mutation, sequence anal-
ysis of the V2R gene was done. Genomic DNA analysis of the
patient revealed a mutation at nucleotide position 1074
(NM_000054), substituting a cytosine for an adenine
(NM_000054). This substitution leads to the introduction of a
premature stop codon (C358X) in the extreme C-terminus of the
V2R. His brother, who also has NDI, harbors the same C358X
mutation, and neither showed increased activity of blood clot-
ting factors upon desmopressin administration (data not
shown). In contrast to the proband, he did not wet his bed after
4 yr of age but went to the toilet three to five times every night
for voiding. The sister of the proband also experienced PNE but
had no signs of impaired renal concentration ability in a con-
centration test, and sequence analysis did not reveal a mutation
in her V2R gene (data not shown). Initiation of desmopressin
administration (20 g intranasally) resolved her PNE.
Cell Biologic Analysis
For determination of the molecular cause of NDI, MDCK
cells, which are an appropriate model for renal principal cells
(13), were stably transfected with constructs that encode wild-
type V2R or V2R-C358X. Both were N-terminally fused to a
FLAG (F) epitope tag to allow detection (from the extracellular
side). Under conditions that would allow detection throughout
the cells, F-V2R expression was easily detected in the basolat-
eral membrane of many stably transfected clones, whereas
F-V2R-C358X expression was not observed (data not shown).
This suggested that V2R-C358X is unstable. For further inves-
tigation of this, COS cells were transiently transfected with
expression constructs that encode F-V2R-GFP and F-V2R-
C358X. Here, the green fluorescence protein (GFP) cDNA was
cloned in frame at the C-terminus of F-V2R and F-V2R-C358X,
which, as a result of the stop codon in F-V2R-C358X, would
yield expression of green F-V2R only. Two days after transfec-
tion, the cells were incubated with anti-FLAG antibodies in
ice-cold PBS for 1 h to label only V2R at the cell surface and
fixed. Parallel-transfected cells were fixed, permeabilized, and
incubated with anti-FLAG antibodies to stain V2R at any loca-
tion. Subsequently, all cells were incubated with secondary
antibodies and subjected to immunocytochemistry. Confocal
laser scanning microscopy analysis revealed that F-V2R-C358X
was not expressed at the cell surface, whereas the F-V2R
showed clear membrane localization (Figure 3, left). Analysis of
permeabilized cells, however, showed expression of F-V2R and
F-V2R-C358X, indicating that V2R-C358X was retained in the
cell and that the lack of plasma membrane expression of V2R-
C358X was not due to the absence of expression (Figure 3,
right). This explains the NDI phenotype in the patients, because
intracellularly retained receptors are not accessible to AVP and,
thus, also not to desmopressin.
To determine semiquantitatively whether V2R-C358X is un-
stable, we analyzed the expression of F-V2R-GFP and F-V2R-
C358X, normalized for their amounts of mRNA. For this, we
transiently transfected COS cells with different amounts of
F-V2R-GFP or F-V2R-C358X expression constructs. After 2 d,
cells were lysed for immunoblotting or total RNA was isolated
and subjected to Northern blotting. As shown in Figure 4, for
similar or somewhat higher levels of F-V2R-C358X mRNA com-
pared with that of F-V2R-GFP (Figure 4, top), the expression
levels of F-V2R-C358X (35 kD) were clearly lower than those of
V2R-GFP (60 and 75 kD; Figure 4 bottom). In fact, the expres-
sion of F-V2R-GFP stayed relatively constant with decreasing
amounts of mRNA, whereas the F-V2R-C358X levels rapidly
Figure 3. V2R-C358X is not expressed in the plasma membrane
of COS cells. Nonpermeabilized or permeabilized (indicated)
COS cells that transiently expressed FLAG-V2R-C358X or
FLAG-V2R-GFP were subjected to immunocytochemistry using
anti-FLAG antibodies, followed by confocal laser scanning mi-
croscopy.
Figure 4. FLAG-V2R-C358X is an unstable protein. COS cells
were transiently transfected with decreasing amounts of ex-
pression constructs for FLAG-V2R-GFP or FLAG-V2R-C358X
(indicated). Subsequently, mRNAwas isolated and subjected to
electrophoresis followed by Northern blotting. V2R mRNAwas
detected using a radioactively labeled V2R probe (top). Of cells
transfected in parallel, lysates were generated and analyzed by
PAGE followed by Western blotting. FLAG-V2R-GFP and
FLAG-V2R-C358X were detected using anti-FLAG antibodies.
Approximate masses (in kD) of the observed bands are indi-
cated on the left. M, mock (transfected). Note the aspecific band
of 70 kD. As found by others, the 120-kD band likely represents
a dimer of V2R.
J Am Soc Nephrol 18: 1534–1539, 2007 Relief of Nocturnal Enuresis by Desmopressin 1537
decreased, which underscores the instability of V2R-C358X
compared with wild-type V2R.
Discussion
Although PNE is common and extensively studied, the cause
of its inherited or sporadic forms remains unknown (14). Three
entirely different therapeutic options (alarm treatment, tricyclic
antidepressants, and desmopressin) have been demonstrated as
being highly efficient in prospective controlled trials, but, re-
gardless of dosage, a group of nonresponders exists for all
treatments. Therefore, for obtaining more insight into this com-
plex disorder, attempts have been made to subgroup PNE.
One classification has been made on the basis of nocturnal
urinary volume or functional bladder capacity and their re-
sponse upon desmopressin treatment (15). This drug has been
used successfully since the 1970s for the treatment of PNE with
the rationale of increased distal tubular water reabsorption and
a consequently reduced nightly urinary volume. This concept
has later been fueled by a study that demonstrated an insuffi-
cient nightly increase in endogenous AVP in some patients
with PNE, leading subsequently to high urinary volume of
poorly concentrated urine (7). Consequently, a low functional
bladder capacity would be rapidly surpassed during sleep,
leading to enuresis, which is reduced by desmopressin. How-
ever, several investigators were not able to divide patients with
PNE into such subgroups or to find positive correlations for
urinary volume and vasopressin levels as predictors for the
desmopressin response in PNE (16). In addition, the largest
study on PNE and desmopressin treatment showed that only
dosage, low voiding frequency, and older age are favorable
factors for dryness upon treatment (17). Therefore, the Stan-
dardization Committee of the International Children’s Conti-
nence Society has recently questioned the clinical usefulness of
such subgrouping approaches (18).
Another hypothesis to explain the cause of some PNE is
detrusor-sphincter dyssynergies and bladder instability, be-
cause some patients with PNE benefit from treatment with
anticholinergics drugs, such as oxybutynin. However, a con-
founding factor here is that these patients also have daytime
symptoms and are therefore not monosymptomatic. Also, sev-
eral studies have suggested a role for idiopathic hypercalciuria
in PNE (19,20). This hypothesis, however, is also highly dis-
puted, because others came to opposite conclusions (21). For all
of these hypotheses, however, it is difficult to rationalize how
desmopressin, the alarm, and tricyclic antidepressants would
relieve nocturnal enuresis if nocturnal enuresis would have a
common cause.
This study and another recent study of ours provide data that
desmopressin, the alarm, and tricyclic antidepressants may act
on the same tissue/organ. We showed that two patients with
PNE and co-segregating NDI as a result of a mutation in the
AQP2 gene responded to the treatment with desmopressin (22).
Although these patients still had large nocturnal urinary vol-
umes, they aroused on the sensation of a full bladder and went
to the bathroom with desmopressin treatment. In this way,
desmopressin has converted PNE into nocturia. Because these
patients have an impaired renal urine concentrating mecha-
nism, reducing the urine volume does not seem to be essential
for the therapeutic effect of desmopressin. However, because
activation of the renal V2R also stimulates sodium and urea
uptake (23,24), a remaining role for renal V2R could not be
completely ruled out.
In this study, we have identified a (novel) V2R mutation as
the underlying cause of NDI in a family, because dehydration
combined with desmopressin administration did not reduce the
urine volume or increase the blood levels of clotting factors in
the patients with NDI. Average urinary osmolalities were as
expected for congenital NDI, and a significant renal concentrat-
ing ability could be excluded. The molecular characterization of
the mutant V2R demonstrated that the encoded protein is un-
stable and does not reach the plasma membrane, where it is
normally bound by AVP or desmopressin to induce the intra-
cellular cAMP signaling cascade.
Of further importance, one of the NDI-affected boys also
experienced PNE. Considering the nonfunctional V2R and the
repetitive replacement of PNE by nocturia after initiation of
desmopressin treatment, our data clearly indicate that the V2R
is not essential for the action of desmopressin in the treatment
of PNE. It has been noted that a placebo-drug effect in PNE is
not negligible. Although we cannot rule out such an effect here,
the rapid recurrence of PNE upon withdrawal and its disap-
pearance again by reintroduction of desmopressin indicate that
the relief of PNE in our patient with PNE-NDI depends on drug
application. Moreover, PNE in our patient seems unrelated to
hypercalciuria, because urinary calcium levels in our patient
were low (Table 1).
Although desmopressin will reduce the nightly urine volume
in patients without NDI-PNE and our data are derived from
one patient only, our results indicate that the success of des-
mopressin in PNE involves neither the renal concentrating
mechanism nor the V2R. It is unclear which receptor/tissue is
involved in this effect. Possibly, desmopressin acts on a protein
in the spinal cord or the neural network of the bladder and the
urethra, because these tissues have been suggested to be in-
volved in nocturnal enuresis (25). More likely, however, des-
mopressin increases arousability by acting on a non-V2R in the
central nervous system, because the alarm treatment and tricy-
clic antidepressants act on the central nervous system, and
increasing evidence is obtained for a delayed central nervous
cortical and brainstem maturational function in children and
adolescents with PNE (26–29). If this holds true, then one of the
best candidate proteins for mediating the action of desmopres-
sin in nocturnal enuresis is the human V1b receptor, because
this protein has a similar affinity for desmopressin as the hu-
man V2R and is localized in the brain (30,31). Determination of
an involvement of the V1b receptor in PNE has to await Food
and Drug Administration–approved specific agonists for this
receptor.
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